<i id='7860305128'><strike id='7860305128'><tt id='7860305128'><pre id='7860305128'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Activists slam private health insurers over coverage restrictions 
Illumina board agrees to spin off Grail, as divestment plans proceed 
How one medical school became remarkably diverse 
Caribou posts encouraging results on off 
Affirmative action in medical school literally saved lives 
Congress needs to close a vaccine 
FDA approval of Sarepta Duchenne genetic therapy gives me hope 
How a Boston hospital is priming medical residents to use GPT 
Virginia high school admissions case could be legal follow 
CMS got Medicare Advantage quality rating wrong, judge rules
Activists slam private health insurers over coverage restrictions 
Senators tussle over abortion against the backdrop of a presidential campaign 
Walensky prepares to leave CDC — and Congress — behind 
Data don't support strong claims for Covid 
Medical records are filled with copy 
